Customer No. **22,852**
Attorney Docket No. **09707.0001**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Kazuo UMEZAWA et al.**	)	
Application No.: **10/519,162**	)	
	)	Group Art Unit: Not Yet Assigned
Filed: **December 23, 2004**	)	
	)	Examiner: Not Yet Assigned
National Stage of International Application No. **PCT/JP2003/008134** under 35 U.S.C. 371	)	
For: **DRUG COMPOSITION CONTAINING NF-κB INHIBITOR**	)	

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08. With the exception of the U.S. patents, a copy of each listed document is attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. WIPO patent publication no. WO 00/30587. An English-language abstract of the document is enclosed.

2. Japanese patent publication no. 10-45738. An English-language abstract of the document is enclosed.

3. Japanese patent publication no. 09-157266. An English-language abstract of the document is enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 21, 2005

By: 
David W. Hill
Reg. No. 28,220

Enclosures
DWH/FPD/blc

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/519,162
				Filing Date	December 23, 2004
				First Named Inventor	Kazuo UMEZAWA
				Art Unit	Not Yet Assigned
(Use as many sheets as necessary)				*Examiner Name*	Not Yet Assigned
Sheet	1	of	3	*Attorney Docket Number*	09707.0001

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,566,394	05-20-2003	Takeuchi et al.	
		US-2004/0259877	12-23-2004	Muto et al.	
		US-5,804,374	09-08-1998	Baltimore et al.	
		US-6,150,090	11-21-2000	Baltimore et al.	
		US-6,410,516	06-25-2002	Baltimore et al.	

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation[6]
		WO 00/26197	05-11-2000	GU et al.		
		WO 99/65449	12-23-1999	CALLAHAN et al.		
		WO 00/30587	06-02-2000	HIRSCH et al.		Abstract
		WO 01/02548	01-11-2001	FORD et al.		
		WO 00/61167	10-19-2000	MUNDY		
		WO 01/47543	07-05-2001	FOXWELL et al.		
		JP 10-045738	02-17-1998	TAKEUCHI et al.		English abstract and English translation
		JP 09-157266	06-17-1997	TAKEUCHI et al.		English abstract and English translation

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/519,162
				Filing Date	December 23, 2004
				First Named Inventor	Kazuo UMEZAWA
				Art Unit	Not Yet Assigned
(Use as many sheets as necessary)				*Examiner Name*	Not Yet Assigned
Sheet	2	of	3	*Attorney Docket Number*	09707.0001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation[6]
		SUMITOMO et al., "INDUCTION OF APOPTOSIS OF CYTOKINE-PRODUCING BLADDER CANCER CELLS BY ADENOVIRUS-MEDIATED IκBα OVEREXPRESSION", Human Gene Therapy, 10, pp. 37-47, (1999).	
		ROMIEU-MOUREZ et al., "ROLES OF IKK KINASES AND PROTEIN KINASE CK2 IN ACTIVATION OF NUCLEAR FACTOR-κB IN BREAST CANCER", Cancer Research, 61, pp. 3810-3818, (2001).	
		YANG et al., "CONSTITUTIVE IκB KINASE ACTIVITY CORRELATES WITH NUCLEAR FACTOR -κB ACTIVATION IN HUMAN MELANOMA CELLS", Cancer Research, 61, 4901-4909, (2001).	
		NARA et al., "ELUCIDATION OF CANCER CACHEXIA-INDUCING FACTOR --FOCUSING ON CYTOKINES--", Growth Factor Division, National Cancer Center Research Institute, Vol. 54, No. 10, pp. 2502-2507, (1999).	
		GHOSH et al., "NF-κB AND REL PROTEINS: EVOLUTIONARILY CONSERVED MEDIATORS OF IMMUNE RESPONSES", Annu. Rev. Immunol., 16, pp. 225-260, (1998).	
		MATSUMOTO et al., "SYNTHESIS OF NF-κB ACTIVATION INHIBITORS DERIVED FROM EPOXYQUINOMICIN C", Bioorganic & Medicinal Chemistry Letters, 10, pp. 865-869, (2000).	
		ALBERT S. BALDWIN, "CONTROL OF ONCOGENESIS AND CANCER THERAPY RESISTANCE BY THE TRANSCRIPTION FACTOR NF-κB", The Journal of Clinical Investigation, Vol. 107, No. 3, pp. 241-246, (2001).	
		ERKEL et al., "INHIBITION OF NF-κB ACTIVATION BY PANEPOXYDONE", Biochemical and Biophysical Research Communications, 226, pp. 214-221, (1996).	
		GEHRT et al., "CYCLOEPOXYDON, 1-HYDROXY-2-HYDROXYMETHYL-3-PENT-1-ENYLBENZENE AND 1-HYDROXY-2-HYDROXYMETHYL-3-PENT-1,3-DIENYLBENZENE, NEW INHIBITORS OF EUKARYOTIC SIGNAL TRANSDUCTION", The Journal of Antibiotics, Vol. 51, No. 5, pp. 455-463, (1998).	
		LIN et al., "INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-κB BY A SYNTHETIC PEPTIDE CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR LOCALIZATION SEQUENCE", The Journal of Biological Chemistry, Vol. 270, No. 24, pp. 14255-14258, (1995).	
		WIPF et al., "SYNTHESIS OF (---)-LL-C10037α AND RELATED MANUMYCIN-TYPE EXPOXYQUINOLS", Synthesis, pp. 1549-1561, (1995).	
		ARIGA et al., "INHIBITION OF TUMOR NECROSIS FACTOR-α-INDUCED NUCLEAR TRANSLOCATION AND ACTIVATION OF NF-κB BY DEHYDROXYMETHYLEPOXYQUINOMICIN", The Journal of Biological Chemistry, Vol. 227, No. 27, pp. 24625-24630, (2002).	
		MASFERRER et al., "ANTIANGIOGENIC AND ANTITUMOR ACTIVITIES OF CYCLOOXYGENASE-2 INHIBITORS", Cancer Research, 60, pp. 1306-1311, (2000).	
		TANAKA et al., "A NOVEL MONOCLONAL ANTIBODY AGAINST MURINE IL-2 RECEPTOR β-CHAIN Characterization of Receptor Expression in Normal Lymphoid Cells and EI-4 Cells", The Journal of Immunology, Vol. 147, pp. 2222-2228, (1991).	
		UMEZWA et al., "ANTICANCER AGENT-RESISTANT FACTORS", Surgery Frontier, Vol. 9, No. 2, pp. 88-91, (2002).	
		ASEA et al., "NOVEL SIGNAL TRANSDUCTION PATHWAY UTILIZED BY EXTRACELLULAR HSP70 Role of Toll-LIKE RECEPTOR (TLR) 2 AND TLR4", The Journal of Biological Chemistry, Vol. 277, No. 17, pp. 15028-15034, (2002).	
		YAN et al., "BENZO[a]PYRENE INDUCES THE TRANSCRIPTION OF CYCLOOXYGENASE-2 IN VASCULAR SMOOTH MUSCLE CELLS", The Journal of Biological Chemistry, Vol. 275, No. 7, pp. 4949-4955, (2000).	
		HISHIKAWA et al., "TOWARDS MOLECULE UNDERSTANDING OF DRUG MECHANISM OF ACTION AND BIOLOGICAL FUNCTIONS", Folia Pharmacol. Jpn. Vol. 118, pp. 197-202, (2001).	
		SEN et al., "MULTIPLE NUCLEAR FACTORS INTERACT WITH THE IMMUNOGLOBULIN ENHANCER SEQUENCES", Cell, Vol. 46, pp. 705-716, (1986).	
		ALBERT S. BALDWIN, JR., "THE NF-κB AND I-κB PROTEINS: New Discoveries and Insights", Annu. Rev. Immunol., 14, pp. 649-683, (1996).	
		BAEUERLE et al., "NF-κB TEN YEARS AFTER", Cell, Vol. 87, pp. 13-20, (1996).	
		BAEUERLE et al., "FUNCTION AND ACTIVATION OF NF-κB IN THE IMMUNE SYSTEM", Annu. Rev. Immunol., 12, pp. 141-179, (1994).	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/519,162
				Filing Date	December 23, 2004
				First Named Inventor	Kazuo UMEZAWA
				Art Unit	Not Yet Assigned
(Use as many sheets as necessary)				*Examiner Name*	Not Yet Assigned
Sheet	3	of	3	*Attorney Docket Number*	09707.0001

NON PATENT LITERATURE DOCUMENTS			
		TAYLOR et al., "THE SYNTHESIS OF ALISAMYCIN, NISAMYCIN, LL-C10037α AND NOVEL EPOXYQUINOL AND EPOXYQUINONE ANALOGUES OF MANUMYCIN A", Synthesis, pp. 775-790, (1998).	
		KIKUCHI et al., "SUPPRESSION OF HORMONE-REFRACTORY PROSTATE CANCER BY A NOVEL NUCLEAR FACTOR κB INHIBITOR IN NUDE MICE", Cancer Research, 63, pp. 107-110, (2003).	
		UMEZAWA et al., "MOLECULAR DESIGN AND BIOLOGICAL ACTIVITIES OF NF-κB INHIBITORS", Molecules and Cells, Vol. 14, No. 2, pp. 163-167, (2002).	
		CHAICHAROENPONG et al., "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF DEHYDROXYMETHYLEPOXYQUINOMICIN ANALOGUES AS INHIBITORS OF NF-κB FUNCTIONS", Bioorganic & Medicinal Chemistry, 10, pp. 3933-3939, (2002).	
		UMEZAWA et al., "NATURALLY OCCURRING AND SYNTHETIC INHIBITORS OF NF-κB FUNCTIONS", Anti-Cancer Drug Design, Vol. 15, No. 4, pp. 239-244, (2000).	
		MATSUMOTO et al., "INHIBITION OF RAT EMBRYO HISTIDINE DECARBOXYLASE BY EPOXYQUINOMICINS", The Journal of Antibiotics, Vol. 53, No. 6, pp. 637-639, (2000).	
		KASAHARA et al., "ANTI-TNFα ANTIBODY 1", Vol. 36, No. 12, pp. 1-7, (2002).	
		MURAKAMI et al., "EFFECTS OF TNF-α AND CELLULAR FUNCTIONS", The Lipid, Vol. 9, No. 5, pp. 1-10, (1998).	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.